Biotest
Biotest AG, a leading player in the biopharmaceutical industry, is headquartered in Dreieich, Germany. Founded in 1946, the company has established itself as a pioneer in the development and production of immunoglobulins and blood plasma products. With a strong focus on therapeutic areas such as immunology and haematology, Biotest is committed to enhancing patient care through innovative solutions. The company’s core offerings include high-quality plasma-derived therapies, which are distinguished by their rigorous quality standards and advanced manufacturing processes. Biotest has achieved significant milestones, including the expansion of its global presence, with operations spanning Europe, North America, and Asia. Renowned for its commitment to research and development, Biotest continues to solidify its market position as a trusted provider of essential biopharmaceuticals, contributing to improved health outcomes worldwide.
DitchCarbon Score
How does Biotest's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biotest's score of 43 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biotest's reported carbon emissions
In 2024, Biotest reported total carbon emissions of approximately 16934800 kg CO2e for Scope 1, about 25092000 kg CO2e for Scope 2 (market-based), and around 92215000 kg CO2e for Scope 3 emissions. This reflects a slight increase in Scope 1 emissions from 15210000 kg CO2e in 2023, while Scope 2 emissions (market-based) also rose from 21905000 kg CO2e in the previous year. The Scope 3 emissions decreased from approximately 102043000 kg CO2e in 2023. Biotest has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company has disclosed emissions data across all three scopes, demonstrating transparency in its climate impact reporting. Overall, Biotest's emissions profile highlights the need for ongoing evaluation and potential strategies to mitigate its carbon footprint, particularly in Scope 3 emissions, which represent the largest portion of its total emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 893,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,537,200 | 000,000 | 000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biotest is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
